2009. Once-daily intravenous busulfan as myeloablative, reduced-toxicity conditioning regimen: results in young and adult patients with hematological malignant and nonmalignant diseases. Hematology Meeting Reports (formerly Haematologica Reports). 2, 6 (Jun. 2009). DOI:https://doi.org/10.4081/hmr.v2i6.771.